Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1976 Nov;34(5):493-9.
doi: 10.1038/bjc.1976.203.

Complement activation in vivo in cancer patients receiving C. parvum immunotherapy

H Biran, J L Moake, R C Reed, J U Gutterman, E M Hersh, E J Freireich, G M Mavligit
Free PMC article

Complement activation in vivo in cancer patients receiving C. parvum immunotherapy

H Biran et al. Br J Cancer. 1976 Nov.
Free PMC article

Abstract

Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46% of the patients. Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (C1) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.

PubMed Disclaimer

References

    1. Am J Med. 1975 Mar;58(3):431-7 - PubMed
    1. N Engl J Med. 1975 Jul 3;293(1):26-32 - PubMed
    1. J Natl Cancer Inst. 1975 Jul;55(1):29-33 - PubMed
    1. Transplant Proc. 1975 Jun;7(2):297-315 - PubMed
    1. Br J Cancer. 1975 Jan;31(1):15-24 - PubMed

Publication types